National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

Core Viewpoint - The National Advertising Division (NAD) is referring claims made by Maze Therapeutics regarding their drug MZE829 to regulatory authorities due to Maze's failure to respond substantively to NAD's inquiry [1][3]. Group 1: Company Overview - Vertex Pharmaceuticals and Maze Therapeutics are competitors in the development of clinical-stage treatments for APOL1-Mediated Kidney Disease (AMKD) [2]. - Maze Therapeutics has made express and implied claims about the efficacy of MZE829 compared to Vertex's drug candidate inaxaplin [2]. Group 2: Regulatory Actions - The NAD's inquiry was prompted by Vertex's request to review Maze's claims about MZE829 [2]. - Maze Therapeutics declined to participate in the NAD process, stating that it does not currently sell any product or advertise MZE829 [3]. - Due to Maze's non-participation, NAD will refer the matter to appropriate government agencies for further action [3].